SAN DIEGO (AP) -- Optimer Pharmaceuticals Inc. said Thursday it received a 10 million euro milestone payment from partner Astellas Pharma, which recently began marketing Optimer's Dificlir anti-infection tablets overseas.
Under the 2011 agreement, Optimer gave Astellas commercial rights for the tablets in Europe, the Middle East and Africa in return for various payments. Dificlir treats clostridium difficile infections in adults, which cause diarrhea and more serious intestinal problems.
Shares of Optimer fell 9 cents to $15.30 in afternoon trading Thursday.
- Astellas Pharma